A 12-month, Multicenter, Randomized, Adaptive Design, Open-label Study To Evaluate The Benefit Of C2 Hour Monitoring Of Neoral On Safety And Efficacy Outcomes In De Novo Cardiac Transplant Recipients Receiving Basiliximab Induction